Wireless EEG and Attention Evaluation System for ADHD

描述(申请人提供)：这个项目的总体目标是开发一种高度便携和定量的神经行为注意力评估设备(NeuroADTM)，用于识别和定量评估患有注意力缺陷多动障碍(ADHD)的儿童/成人以及与睡眠呼吸障碍(SDB)相关的ADHD样症状的儿童的药物/治疗。ADHD和SDB是儿童中比较常见的问题。打鼾症、ADHD和SDB的患病率分别为10%、7%和2%。此外，最近的研究表明，15%-25%的ADHD诊断可能是未被识别的SDB的次要疾病。目前还没有针对ADHD的独立诊断测试，目前的诊断方法有些主观。NeuroAD通过将高度便携的多通道无线脑电采集和分析设备与基于听觉的注意力测试和先进的信号处理算法相结合，提供了一种客观、实用和定量的评估ADHD的手段。15分钟的测试方案几乎可以在任何地点实施(初级保健医生/儿科医生办公室/诊所、精神科医生办公室/诊所等)。第一阶段的工作包括在正常和ADHD、儿童和成人的一些临床研究中成功地实施了多EEG NeuroADTM。NeuroADTM S将脑电相关变量与行为反应曲线相结合的新算法和判别指数，已被证明在区分正常儿童和患有ADHD和ADHD样症状的儿童方面非常有效。第二阶段的工作重点是完成和微调第一阶段开发的硬件/软件/算法。此外，我们还将开发NeuroADTM，这将是一个使用NeuroADTM S硬币大小的脑电设备的微型配置。这种高度便携且易于使用的设备将使用商用手持PDA以及易于连接的头带，以便快速方便地放置电极。该系统将对成人和儿童受试者(正常、ADHD用药前和用药后，以及SDB腺体扁桃体切除术前后)进行广泛的多中心临床评估。这些测试的结果将组合在一起进行全面的统计分析，以证明NeuroADTM在筛查和识别ADHD以及评估药物/治疗效果方面的有效性。在该项目下开发的神经行为注意评估设备(Neurobehavior Attendant Value Device，简称NeuroADTM)旨在作为一种可移动的、易于使用的、高度定量的方法来筛查ADHD的存在，并评估药物/治疗的效果。这项15分钟的测试几乎可以在任何地点进行(初级保健医生/儿科医生办公室/诊所、精神科医生办公室/诊所等)。并有可能将ADHD与由睡眠呼吸暂停和其他睡眠呼吸紊乱引起的ADHD样症状区分开来。

DESCRIPTION (provided by applicant): The overall aim of this project is to develop a highly portable and quantitative Neurobehavioral Attention Evaluation Device (NeuroADTM) for the identification and quantitative evaluation of medication/therapy in children/adults with attention deficit hyperactivity disorder (ADHD), as well as children with ADHD-like symptoms related to sleep disordered breathing (SDB). ADHD and SDB are relatively common problems in children. The prevalence of snoring, ADHD, and SDB are 10%, 7%, and 2% respectively. Furthermore, recent studies have suggested that 15-25% of ADHD diagnoses may be secondary to unrecognized SDB. There is currently no independent diagnostic test for ADHD and the current method of diagnosis is somewhat subjective. NeuroAD provides an objective, practical, and quantitative means of assessing ADHD by combining a highly portable multi-channel wireless EEG acquisition and analysis device with an auditory-based test of attention and advanced signal processing algorithms. The 15 minute test protocol can be administered at virtually any location (primary care physician/pediatrician office/clinic, psychiatrists' office/clinic, etc.). Phase I effort involved the successful implementation of the Multi-EEG NeuroADTM in a number of clinical studies with both normal and ADHD, children and adults. NeuroADTM s novel algorithms and discriminating indices, which combine EEG-related variables with the profile of the behavioral response, have been shown to be very effective in distinguishing normal children from children with ADHD and ADHD-like symptoms. Phase II effort centers around finalizing and fine-tuning the hardware/software/algorithms developed in Phase I. In addition, we will develop NeuroADTM which will be a miniaturized configuration using NeuroADTM s coin-sized EEG device. This highly portable and easy-to-use device will utilize a commercial hand-held PDA along with an easy-to-attach headband for fast and convenient placement of the electrodes. This system will undergo extensive multi-center clinical evaluations with adult and children subjects (normal, ADHD pre- and post-medication, and SDB pre- and post-adenotonsillectomy). The results of these tests will be grouped together to perform a comprehensive statistical analysis to demonstrate the effectiveness of NeuroADTM in screening and identifying of ADHD and evaluating the effects of medication/therapy. The Neurobehavioral Attention Evaluation Device (NeuroADTM) that is being developed under this project is aimed to be utilized as an ambulatory, easy-to-use, and highly quantitative method to screen for the presence of ADHD and evaluating the effects of medication/therapy. The 15-minute test can be administered at virtually any location (primary care physician/pediatrician office/clinic, psychiatrists' office/clinic, etc.) and has the potential to differentiate ADHD from ADHD-like symptoms caused by sleep apnea and other sleep disordered breathing.